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Three mechanisms have been proposed for the role of glutathione (GSH) in regulating cisplatin (CDDP) sensitivities that
aﬀects its ultimate cell-killing ability: (i) GSH may serve as a cofactor in facilitating multidrug resistance protein 2- (MRP2-)
mediated CDDP eﬄux in mammalian cells, since MRP2-transfected cells were shown to confer CDDP resistance; (ii) GSH may
serve as a redox-regulating cytoprotector based on the observations that many CDDP-resistant cells overexpress GSH and γ-
glutamylcysteine synthesis (γ-GCS), the rate-limiting enzyme for GSH biosynthesis; (iii) GSH may function as a copper (Cu)
chelator. Elevated GSH expression depletes the cellular bioavailable Cu pool, resulting in upregulation of the high-aﬃnity Cu
transporter (hCtr1) which is also a CDDP transporter. This has been demonstrated that overexpression of GSH by transfection
with γ-GCS conferred sensitization to CDDP toxicity. This review describes how these three models were developed and critically
reviews their importance to overall CDDP cytotoxicity in cancer cell treatments.
1.Introduction
Cisplatin (CDDP) has been the mainstay for the treatment
of a broad spectrum of human malignancies since it was
approved by the FDA about 30 years ago. It has been used in
the ﬁrst-line treatment modalities of human malignancies,
including testicular [1], ovarian [2, 3], cervical [4], bladder
[5], head and neck [6], and small cell lung cancers (SCLCs)
[3, 7, 8]. However, many patients eventually relapse and
develop resistance to the treatment. Once patients develop
resistance to platinum (Pt) drugs, other eﬀective treatment
options become limited. It is well known that CDDP acts
on multiple cellular targets representing diverse signal trans-
duction pathways. It is therefore conceivable that multiple
mechanisms are involved in CDDP resistance, including
reduction of drug transport and increased DNA adduct
tolerance and repair [9, 10].
In this review, we focus on the role of glutathione (GSH)
system in CDDP resistance. Three principal mechanisms
are discussed here. The ﬁrst mechanism involves the eﬀects
of GSH on the ATP-binding cassette (ABC) transporter-
mediated CDDP transport; the second mechanism involves
the redox-regulating capacity of GSH in detoxifying CDDP
toxicity; the third mechanism involves regulation of the
intracellular copper pool that aﬀects CDDP uptake.
2. Role of GSH in ABC Transporter-Mediated
CDDP Transport
The ABC transporters are a family of cytoplasmic
membrane-spanned proteins that function as eﬄux pumps
for eliminating antitumor agents, xenobiotics, and anionic
lipophilic endogenous constituents [11–13]. Therefore,
many of these transporters are also known as multidrug
resistance proteins (MRPs). These transporters utilize ATP
hydrolysis as energy source for substrate elimination [11].
Some transporters require GSH for substrate transport [11].
GSH may serve as substrate for conjugation reaction with2 Metal-Based Drugs
CDDP prior to MRP-mediated transport. Ishikawa and
Ali-Osman [14]ﬁ r s tr e p o r t e dt h ef o r m a t i o no faP t ( G S ) 2
conjugate in L1210 leukemia cells. These investigators
also reported that elimination of Pt(GS)2 across the
membrane requires ATP, suggesting the involvement of an
energy-dependent transporter of GSH-conjugate (termed
GS-X pump) [15] in the elimination of Pt(GS)2 complex.
Later, gene encoding MRP2, member ABCC2 in the ABC
transporter family, was cloned; it was found that transfection
of MRP2 into HEK-293 cells conferred CDDP resistance
(10-fold) in the transfected cells [16]. MRP2-mediated eﬄux
requires GSH [17]. These results demonstrated that MRP2 is
the GS-X pump for the elimination of CDDP.
MRP2, like MRP1, can also transport GSSG itself, an
oxidized form of GSH, with relatively higher aﬃnity than
does GSH [18,19].Thus,theseABCtransporterscanbecon-
sidered as regulators of intracellular GSSG-GSH homeostasis
and the associated redox maintenance (see below). Many
studies have demonstrated direct interactions between GSH
and ABC transporters [20, 21], suggesting that GSH may
induceconformationalchangesthatfacilitateMRP-mediated
substrate transport [11].
MRP2 is also known as a canalicular multispeciﬁc
organic anion transporter (cMOAT) because of its high level
of expression in the hepatic canalicular compartment and
because it mediates the transport of a broad spectrum of
nonbile salt organic anions from the liver into bile. cMOAT-
deﬁcient (TR-) Wistar rats are mutated in the gene encoding
MRP2, leading to defective hepatobiliary transport of a
whole range of substrates, including bilirubin glucuronide.
MRP2 mRNA and protein levels can be markedly
induced by treatments with metalloid salts including sodium
arsenite [As(III)] and potassium antimonyl tartrate in pri-
mary rat and human hepatocytes [22]. Expression of MRP2
in primary rat hepatocytes is also induced by CDDP [23].
In one study, a single subcutaneous injection of CDDP
(5mg/kg) into Male Sprague-Dawley rats resulted in >10-
fold induction of MRP2 in renal brush-border membranes
within one day of treatment whereas nonsigniﬁcant induc-
tion of MRP2 levels was found in the livers [24]. In normal
rats, ∼47%oftheinitialCDDPdoseisexcretedbythekidney
whereas 1%–5% is excreted by the liver. The ﬁnding that
increased expression of MRP2 in renal BBM upon injection
of CDDP suggests that this transporter may be involved in
the excretion of CDDP by the kidney. Since levels of MRP2
arealreadyhighinthehepatocytes,thismayexplainwhyonly
marginal increases of MRP2 was seen in the livers of CDDP-
treated animals [24]. Moreover, a recent report showed that
elevated MRP2 levels seemed to aﬀect the eﬃcacy of CDDP-
based chemotherapy in hepatocellular carcinoma HCC [25].
While Ishikawa and Ali-Osman [14] initially reported
that formation of Pt(GS)2 complex reached a maximal
level after 12hrs in L1210 cells treated with 20μM CDDP,
corresponding to ∼60% of the intracellular Pt content,
however, Berners-Price and Kuchel studied the reaction of
CDDP with GSH inside intact red blood cells using 1H
spin-echo nuclear magnetic resonance (NMR) and detected
no formation of Pt-GSH bonds within 4hrs of incubation
[26]. Recently, Kasherman et al. [27] studied the interactions
of CDDP with cell extracts prepared from ovarian cancer
cells and found very little Pt(GS)2 by the [1H,15N]HSQC
approach. Since CDDP can bind to many thiol-containing
proteins and its primary cytotoxic target DNA, once inside
the cells, these cellular constituents will compete against
GSH for CDDP binding. These investigators found that the
majority of glutathionated complexes were in fact in high
molecular mass fraction (whereas the molecular mass of
Pt(GS)2 is 809). Therefore, the signiﬁcance of GSH-CDDP
binding as an important step for CDDP elimination remains
somewhat controversial.
3. Role of the GSH System as a Cytoprotector in
CDDP Resistance
GSH is an abundant thiol-containing tri-peptide (Glu-
Cys-Gly), constituting 1∼10mM in mammalian cells. De
novo biosynthesis of GSH is controlled by the rate-limiting
enzyme, glutamate-cysteine ligase (GCL, also known as γ-
glutamylcysteine synthetase, γ-GCS) which consists of a
catalytic (heavy) (γ-GCSh) and a regulatory (light) subunit
(γ-GCSl). γ-GCS carries out the initial ligating reaction of
glutamine (Glu) and cysteine (Cys). Production of GSH is
accomplished by the subsequent reaction involving glycine
(Gly) by GSH synthetase (Figure 1). GSH can be oxidized
into GSSG by GSH peroxidase using H2O2 as a substrate
whereas GSSG can be reduced back to GSH by GSSG
reductase using NADPH as a cofactor. Therefore, GSH-
GSSG system provides an important redox buﬀer in living
organisms.
As alluded to earlier, the transport activity of MRP2
(and other members of the MRP family) is regulated by
GSH availability. Since γ-GCS is the rate-limiting enzyme for
the biosynthesis of GSH, coregulation of γ-GCS and MRPs
would facilitate the eﬄux activity (Figure 1). Indeed, we
found that a number of cytotoxic agents can simultaneously
induce the expression of both γ-GCSh and MRP, including
CDDP [28], carcinogens [29], and prooxidants [30, 31].
Furthermore, enhanced expression of γ-GCSh/MRP1 was
found in colorectal cancers, which are associated with
inﬂammation-associated oxidative stress [32, 33]. These
observations, taken together, strongly suggest that GSH/γ-
GCS system is a molecular sensor of oxidative stress condi-
tions [11].
3.1. Frequent Upregulation of GSH and γ-GCS in CDDP-
Resistant Variants. Previous studies have reported that expo-
sure of cultured cells to CDDP led to the development
of CDDP resistance which was correlated with increased
cellular GSH levels [34–39]. Moreover, GSH depletion by
buthionine-sulfoximine (BSO) has been associated with
increased sensitivity to CDDP [8, 14–17]. In many cases,
when γ-GCS mRNA contents were measured, elevated
levels of γ-GCSh mRNA were also correlated with CDDP
resistance. These studies have been widely taken as that
intracellular GSH levels play an important role in regulating
CDDP resistance [34, 40–43], perhaps through a GSH-
mediated cytoprotective mechanism. However, molecularMetal-Based Drugs 3
mechanisms as how GSH functions as a cytoprotector for
CDDP resistance have not been elucidated.
However, this proposition has several caveats. One,
these studies frequently used CDDP-treated cells and the
observations were mostly correlative in nature. Whether
elevated expression of GSH indeed is causally responsible for
the CDDP resistance needs to be critically evaluated. Two,
as alluded to above, induction of γ-GCS, and thus GSH,
in CDDP-treated cells may be an oxidative stress-induced
phenomenon because γ-GCS/GSH is a sensor/regulator of
reactive oxygen species (ROSs) imbalance, and its expression
can be induced by a wide array of cytotoxic insults. In many
cases, elevated expression of γ-GCS/GSH under cytotoxic
insult did not confer CDDP resistance in the treated cells
[44]. Three, also as alluded above, normal cells usually con-
tainmillimolarlevelsofGSH.Stoichiometrically,theseabun-
dantamountsofthiolcompoundmayalreadybesuﬃcientto
neutralize the cytotoxic eﬀects of CDDP which are usually in
micromolar ranges. Thus, increased GSH content found in
most of CDDP-treated cells may not necessarily have a major
impact in the detoxiﬁcation mechanism of CDDP. As will be
described below, we found that elevated expression GSH per
se induces cellular sensitization to CDDP treatment [45].
3.2. Mechanisms of Upregulation of γ-GCS/GSH by Oxidative
Stress. Both transcriptional regulation and posttranscrip-
tional regulation have been reported for the upregulation of
γ-GCSh by various cytotoxic assaults. Transcriptional regu-
lation is mediated by an antioxidant response element (ARE,
5 -TGAGTCA) located at the promoter of the γ-GCSh allele,
which interacts with the NF-E2-related transcription factor
(Nrf2). Under unstressed conditions, majority of Nrf2 is in
the cytosol and bound to Kelch-like ECH-associated protein
(Keap1) which functions as a substrate adaptor for a Cullin-
dependent E2 ubiquitin ligase complex and targets Nrf2 for
ubiquitination and proteasomal degradation. Because Keap1
is a redox-sensitive E3 ligase, oxidative stress conditions
induce Keap1 sulfhydryl group modiﬁcation and conforma-
tional changes, resulting in Nrf2 release from proteasomal
degradation and allowing it to translocate to the nucleus
[46]. By heterodimerizing with the small Maf protein as
coactivator, together, they bind to the ARE and transactivate
γ-GCSh expression. Expression of MRP2 is also apparently
regulated by Nrf2 signal. Livers from hepatocyte-speciﬁc
Gclc/γ-GCSh-knockout mice showed elevated expression of
Nrf2 and MRP2 due to elevated oxidative stress [47].
Regulation of γ-GCSh by oxidative stress is also con-
trolled by posttranscriptional signal. We demonstrated that
oxidativestressinducesγ-GCShmRNAstabilizationthrough
the p38 MAP kinase pathways. Under oxidative stress
conditions, P38 MAP kinase activates MAPKAPK2, which
promotes translocation of mRNA-stabilizing factor HuR
from the nucleus to the cytoplasmic compartment, where it
stabilizes γ-GCSh mRNA by binding to the AU-rich motif
located at the 3  untranslated region. The accumulated γ-
GCSh mRNA produces elevated levels of GSH that feed back
to suppress γ-GCSh mRNA stabilization [44] and the Nrf2
signal-mediated γ-GCSh transcription as mentioned above.
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Figure 1: The role of GSH in MRP-mediated CDDP transport. De
novobiosynthesisofGSHiscarriedoutbyγ-GCS,whichconjugates
glutamine (Glu) and cysteine (Cys) followed by GSH synthetase
using glycine (Gly) as a substrate. GSH can be oxidized into GSSG
by GSH peroxidase. SOD refers to superoxide dismutase. GSSG can
be reduced to GSH by GSSG reductase. GSSG is a substrate of the
MRP/GS-X pump whereas GSH functions as a cofactor for MRP-
mediated CDDP transport.
4. Role of GSH in Human High-Afﬁnity
CuTransporter-(hCtr1-) Mediated
CDDP Transport
In 1998, while we were studying the coregulation of γ-
GCSh and MRP1 by CDDP, we found that transfection
of recombinant DNA encoding the γ-GCSh subunit alone
was suﬃcient to enhance GSH levels in the transfected
cells [29]. Surprisingly, we also found that these stable γ-
GCSh-transfected cells exhibited hypersensitivity instead of
resistance to the toxicity of CDDP. Hypersensitivity to the
toxic eﬀect of CDDP was associated with enhanced uptake
of CDDP in these transfected cells. However, transporter
for the uptake of CDDP was not available at the time.
CDDP transporter was later identiﬁed as the high-aﬃnity
Cu transporter (hCtr1) [48] and the mechanism of this
hypersensitization was due to the upregulation of hCtr1 in
these transfected cells [45] (see below).
4.1.IdentiﬁcationofhCtr1asCDDPTransporter. Transporter
for CDDP was identiﬁed using a genetic screening approach.
Ishida et al. [48] mutagenized yeast cells with a transpose
library after selecting mutants that were able to grow
in the presence of a toxic dose of CDDP. One of the
mutants was defective in the Mac1 gene which encodes
a copper concentration-dependent transcription factor for
the expression of several genes involved in the uptake
of iron and copper [49]. These investigators subsequently
determined that yCtr1 is the target gene that could reca-
pitulate the CDDP-resistance phenotype observed in the
mac1Δ mutant. Likewise, murine embryonic ﬁbroblasts
derived from mCtr1(−/−) animals exhibited reduced CDDP4 Metal-Based Drugs
accumulation as compared with their respective wild-type
counterparts.
The discovery that Ctr1 is involved in Pt drug transport
underscores the important role of Cu metabolism in the
eﬃcacy of Pt drug chemotherapy. Copper is an essential
micronutrient for cell survival, yet Cu overload is toxic. To
meet their need for Cu while avoiding toxicity, all living
organisms from yeast to humans have developed an evolu-
tionarily conserved system to regulate Cu homeostasis. This
system consists of a transporter (Ctr1) for Cu acquisition,
chaperones (HAH1, COX17, and CCS) for Cu delivery to
various intracellular compartments, and exporters (ATP7A
and ATP7B) for Cu elimination (Figure 2). Although Cu
entry can also be carried out by divalent metal transporter 1
(DMT1), which transports a broad range of divalent metal
ions including Cu(II), the majority of Cu acquisition is
accomplished by Ctr1, which transports Cu(I). The Belgrade
rat, which has a mutation in dmt1, has no Cu-deﬁcient
phenotype [50]. Extracellular Cu exists in the oxidized
form [Cu(II)] which is converted into Cu(I) by membrane-
bound cupric reductases, relevant to the yeast Fre1 and Fre2
reductases [51, 52], for hCtr1-mediated transport.
Ctr1 plays an important role in the regulation of
intracellular Cu homeostasis. This was ﬁrst demonstrated
in yeast. Expression of yeast Ctr (yCtr1 and yCtr3)i st r a n -
scriptionally upregulated under Cu-deplete conditions and
is downregulated under Cu-replete conditions. During Cu-
depleted conditions, the transcription factor Mac1p binds
to the metal binding sequence [5 -TTTGC(T/G)C(A/G)]
located at the promoters of yCtr1 and yCtr3 [53–55]
and turns on the expression of these genes. Under Cu-
replete conditions, Mac1 dissociates from the promoters,
resulting in shut-down of the expression of yCtr1 and
yCtr3. In the meantime, the transcription factor Ace1 is
activated to induce the expression of genes encoding Cu-
chelating proteins (Cup1 and Crs5) and the antioxidant
superoxide dismutase (SOD1) [56–58] to protect cells from
Cu overload. Both Mac1 and Ace1 contain zinc ﬁnger (ZF)
motifs that function as metallosensors. A transcriptional
regulation mechanism is also involved in Cu(I)-dependent
regulation of the Drosophila CtrB gene [59], a homologue of
yCtr1 and yCtr3. In addition to transcriptional regulation,
posttranslational regulation has been reported for yCtr1 and
yCtr3 proteins in response to Cu stress [60].
Available information in the literature regarding the
mechanisms of regulation of human copper transporter
(hCtr1) is controversial. It has been reported that regulation
of mammalian Ctr1 is controlled at the posttranslational
levels. Elevated Cu levels induce the traﬃcking of hCtr1
from the plasma membrane to endosomal/lysosomal com-
partments where Ctr1 is degraded [61, 62].
We investigated the regulation of hCtr1 expression in
response to Cu concentration stress and found that levels
of hCtr1 mRNA were decreased in cultured small cell lung
cancer (SCLC) cells treated with CuSO4 but were increased
in cells treated with the Cu-depleting agent bathocuproine
disulfonic acid. We further demonstrated that the ZF
transcription factor Sp1 plays an important role in the
transcriptional regulation of hCtr1 [63]. These results, taken
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Figure 2: The eﬀects of γ-GCSh overexpression on cellular Cu
metabolism and CDDP transport. Overexpression of γ-GCSh,
which catalyzes the ligation of cysteine (Cys) and glutamate
(Glu), results in increased GSH levels. Excess GSH functions as
a Cu depletor, as evidenced by the reduction in CCO and SOD
activity, and holo-ceruloplasmin (Cu-Cpm) contents. Intracellular
Cu deﬁciency upregulates hCtr1 expression, which is regulated by
transcription factor, Sp1. Upregulation of hCtr1 enhances CDDP
uptake, resulting in elevated sensitivities to CDDP treatment. CCS,
HAH1, and COX17 are Cu chaperones that shuﬄeC ut ot h e i r
respective targets as indicated by arrows.
together, indicate that expression of hCtr1 is upregulated
under copper deplete condition but is downregulated under
copper replete conditions.
4.2. Mechanism of Sensitization of GSH-Overproducing Cells
to CDDP Treatment. The ﬁndings that hCtr1 expression is
regulated by intracellular Cu bioavailability prompted us
to investigate whether sensitization of GSH-overproducing
cells in the γ-GCSh-transfected cells to CDDP was due
to reduced intracellular bioavailable Cu contents, resulting
in upregulation of hCtr1 expression. It has been well
established that Cu can form a Cu-GSH complex by directly
interacting with its internal cysteine-SH residue of GSH.
However, unlike formation of Pt(GS)2, formation of Cu(GS)
is almost a spontaneous reaction and requires no enzy-
maticinvolvement[63–65],resultinginreducedintracellular
bioavailability of Cu levels. We found that the γ-GCSh-
transfected cells indeed showed Cu deﬁciency as evidenced
by the reduced enzymatic activities of Cu, Zn superoxide
dismutase (SOD1) and mitochondrial cytochrome C oxidase
(CCO) as compared with those in the nontransfected cells
[45]. Moreover, reduction of Cu content in ceruloplasmin, a
copper-containing ferroxidase that plays an important role
in mammalian iron homeostasis, was also found in the
transfected cells. These enzymatic markers have been used
as biochemical signature for intracellular Cu bioavailability
[66]. Levels of hCtr1 expression in the three indepen-
dently established γ-GCSh- t r a n s f e c t e dc e l l sw e r e3 -t o4 -
fold increases as compared with that in the parental cells.
No substantial decreases in ATP7A or ATP7B levels were
observed. Moreover, increased hCtr1 expression in these γ-
GCSh-transfected cells was associated with enhanced CDDP
uptake [45].Metal-Based Drugs 5
Sensitization of γ-GCSh-transfected cells to CDDP could
be reversed when these cells were treated with GSH-
depleting agent buthionine-sulfoximine (BSO). This reversal
was associated with the reduced expression of hCtr1 due to
the reinstated Cu bioavailability in the transfected cells as
analyzed by activities of the Cu signature enzymes [45].
Taken together, our ﬁnding demonstrated that elevated
levels of GSH per se can sensitize CDDP toxicity. The eluci-
dation that GSH functions as a Cu chelator in upregulating
its transporter hCtr1 has important implications in cancer
chemotherapy using platinum-based antitumor agents. We
note that recent report has shown that another copper
chelator, tetrathiomolybdate, can enhance CDDP sensitivity
in ovarian cancer animal model [67].
5. Conclusion andFutureProspective
The three major mechanisms that control CDDP sensitivity
by GSH described in the paper reﬂect the complexity of
a small peptide that can regulate the eﬃcacy of CDDP
toxicity. The signiﬁcance of each of these mechanisms
may depend upon various cell types and/or diﬀerent cell
physiologic conditions. As alluded to above, CDDP can
interact with many cellular targets and aﬀect many signal
transduction pathways to elicit its cytotoxicity. Likewise,
GSHisanimportantredoxregulatorandredoxsignalingcan
aﬀect many important cellular processes [11]. Thus, GSH
may have far-reaching eﬀects on CDDP sensitivity. Future
investigations are needed to address the roles of GSH in the
global eﬀects of CDDP sensitivity.
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